Platte River Capital’s AstraZeneca AZN Stock Holding History

Platte River Capital’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-6,500	Closed	-$422K	–	203
2014 Q1	$422K	Sell	6,500 -41,690	-87%	-$2.69M	0.06%	174
2013 Q4	$2.86M	Sell	48,190 -10,500	-18%	-$570K	0.37%	100
2013 Q3	$3.05M	Sell	58,690 -10,500	-15%	-$527K	0.38%	98
2013 Q2	$3.27M	Buy	+69,190	New	+$3.52M	0.38%	99

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

MCM

Mason Capital Management New York $607M AUM 1.77% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

SCCM

Schafer Cullen Capital Management New York $491M AUM 41.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Platte River Capital's AZN Position: Q2 2014 in Review

Platte River Capital sold out of AstraZeneca (AZN) in Q2 2014, closing a stake of 6,500 shares — an estimated $422K sold.

Platte River Capital first reported a position in AZN in Q2 2013 and held it in 4 quarters. The position peaked at $3.27M in Q2 2013. 419 funds tracked by Wall St. Rank hold AZN as of Q2 2014.

Platte River Capital reported no remaining AstraZeneca position as of Q2 2014 after selling out during the quarter.
Platte River Capital sold 6,500 AstraZeneca shares in Q2 2014, an estimated $422K.
Platte River Capital first reported a position in AstraZeneca in Q2 2013 and held it in 4 quarters.
Platte River Capital's AstraZeneca position peaked at $3.27M in Q2 2013.
419 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2014.

Based on Platte River Capital's 13F filing for Q2 2014, filed 29 Jul 2014.